^
Association details:
| Biomarker: | HER-2 L755_T759del |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.
Published date:
05/16/2018
Excerpt:
There were three cases identified where HER2 mutation status impacted the selection of personalized anti-HER2 therapies….Case 2 was a HER2-negative patient with an ERBB2 mutation (p.L755_T759del) was response to afatinib and trastuzumab.
DOI:
10.1200/JCO.2018.36.15_suppl.1039
